Reference

1. Steck O, et al. Current and emerging role of artificial intelligence in regulatory intelligence. In: Sistema W, Ashraf D, eds. Regulatory Intelligence 101. 3rd ed. Regulatory Affairs Professionals Society; 2021:179-186.
2. Schultz M. Lessons Jack Welch taught me about being a business leader Medium website. https://medium.com/@mikeschoultz/lessons-jack-welch-taught me-about-being-a- business-leader-4589a6a383f4 Published 29 December 2015. Accessed 28 April 2021
3. Messmer K. Background and skill set needed for a regulatory intelligence professional. In: Sistema W, Ashraf D, eds. Regulatory Intelligence 101. 3rd ed. Regulatory Affairs Professionals Society; 2021:23-32.
4. Meredith Brown-Tu0le,RAC,Regulatorium.comtheregulatorium@gmail.com.
5. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Save. 2006;29:385–396.
6. https://www.google.com/url?sa=t&source=web&rct=j&url=https://capra.ca/_uploads/581ce1598d352.pdf&ved=2ahUKEwicy_GX8571AhUfUGwGHVzsB2AQFnoECBoQAQ&usg=AOvVaw3MTrBZprNW-J6Js4fha5na (www.capra.com).
7. Www.Pda.Org(https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.pda.org/docs/default-source/website-documentlibrary/chapters/presentations/west-coast/regulatory-intelligence-101.pdf?sfvrsn=132b48e_4&ved=2ahUKEwi5z-al9J71AhWQGqYKHcEhCYsQFnoECCcQAQ&usg=AOvVaw32CwvJLCzvsPwzDlZMY6oU).
8. Hammond sunnah (senior regulatory intelligence expert)27junewww.thombsonreuters.com(2019https://www.google.com/urlsa=t&source=web&rct=j&url=https://www.thomsonreuters.com/en-us/posts/investigation-fraud-and-risk/cost-of-compliance-survey-regulatory-change-2019/&ved=2ahUKEwjOt7vC9Z71AhXDIqYKHb2PDpIQFnoECCQQAQ&usg=AOvVaw3 ucicCglpVx8AsigXtK_TF).
9. Raps.org Evaluation of regulatory intelligence profession posted on 29 April 2021 By Danish Ashraf dharma d and Kirsten messmer phd,RAC
10. Hamburg MA. Innovation, regulation, and the FDA. N Engl J Med. 2010; 363(25):2228- 32.
11. Van Grootheest K, Dukes G. Leopold Meyler (1903-1973): a pioneer in the study of adverse effects of drugs. Int J Risk Saf Med. 2003/2004;16:67-70.
12. The importance of pharmacovigilance-safety monitoring of medicinal products. Geneva: World Health Organization; 2002. Available at:https://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Accessed on 01 July 2020.
13. Dr. V Pannikar. The Return of Thalidomide: New Uses and Renewed Concerns. WHO Pharmaceuticals News letter.2003;2. Available at: https://www.who.int/lep/research/Thalidomide.pdf. Accessed on 01 July 2020
14. Pharmacovigilance: Ensuring the Safe Use of Medicines - WHO Policy Perspectives on Medicines,No.009, October2004. Available at:http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf. Accessed on 01 July 2020. WHOcc in Uppsala (UMC). Available at:https://www.who.int/medicines/areas/quality_safety/safety_efficacy/PV_fast_facts/en/.Ac cussed on 01 July 2020.
15. Lazaro J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
16. Institute of Medicine. Preventing medication errors. 2006.Available at: http://www.iom.edu/~/media/Files/Report Files/2006/Preventing-Medication-Errors- Quality-Chasm-Series/medicationerrorsnew.pdf. Accessed on 01 July 2020
17. Gor AP, Desai SV. Adverse Drug Reactions (ADR) in the in Patients of Medicine Department of a Rural Tertiary Care Teaching Hospital and Influence of Pharmacovigilance in Reporting ADR. Indian J . 2008:40(1):37-40.